Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

Am J Trop Med Hyg. 2020 Dec;103(6):2419-2428. doi: 10.4269/ajtmh.20-1240. Epub 2020 Oct 2.

Abstract

Little is known about the clinical features and outcomes of SARS-CoV-2 infection in Africa. We conducted a retrospective cohort study of patients hospitalized for COVID-19 between March 10, 2020 and July 31, 2020 at seven hospitals in Kinshasa, Democratic Republic of the Congo (DRC). Outcomes included clinical improvement within 30 days (primary) and in-hospital mortality (secondary). Of 766 confirmed COVID-19 cases, 500 (65.6%) were male, with a median (interquartile range [IQR]) age of 46 (34-58) years. One hundred ninety-one (25%) patients had severe/critical disease requiring admission in the intensive care unit (ICU). Six hundred twenty patients (80.9%) improved and were discharged within 30 days of admission. Overall in-hospital mortality was 13.2% (95% CI: 10.9-15.8), and almost 50% among those in the ICU. Independent risk factors for death were age < 20 years (adjusted hazard ratio [aHR] = 6.62, 95% CI: 1.85-23.64), 40-59 years (aHR = 4.45, 95% CI: 1.83-10.79), and ≥ 60 years (aHR = 13.63, 95% CI: 5.70-32.60) compared with those aged 20-39 years, with obesity (aHR = 2.30, 95% CI: 1.24-4.27), and with chronic kidney disease (aHR = 5.33, 95% CI: 1.85-15.35). In marginal structural model analysis, there was no statistically significant difference in odds of clinical improvement (adjusted odds ratio [aOR] = 1.53, 95% CI: 0.88-2.67, P = 0.132) nor risk of death (aOR = 0.65, 95% CI: 0.35-1.20) when comparing the use of chloroquine/azithromycin versus other treatments. In this DRC study, the high mortality among patients aged < 20 years and with severe/critical disease is of great concern, and requires further research for confirmation and targeted interventions.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Asymptomatic Diseases
  • Azithromycin / therapeutic use
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology*
  • COVID-19 / mortality*
  • COVID-19 Drug Treatment
  • Chloroquine / therapeutic use
  • Democratic Republic of the Congo / epidemiology
  • Drug Combinations
  • Enoxaparin / therapeutic use
  • Female
  • Hospital Mortality / trends*
  • Hospitalization / statistics & numerical data
  • Hospitals
  • Humans
  • Intensive Care Units
  • Lopinavir / therapeutic use
  • Male
  • Middle Aged
  • Obesity / diagnosis
  • Obesity / physiopathology
  • Obesity / virology
  • Pandemics*
  • Patient Discharge / statistics & numerical data
  • Renal Insufficiency, Chronic / diagnosis
  • Renal Insufficiency, Chronic / physiopathology
  • Renal Insufficiency, Chronic / virology
  • Retrospective Studies
  • Risk Factors
  • Ritonavir / therapeutic use
  • SARS-CoV-2 / pathogenicity*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Drug Combinations
  • Enoxaparin
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Azithromycin
  • Chloroquine
  • Ritonavir